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ii 
Protease activity has been demonstrated to be an important prognostic and 
predictive marker in diseases such as cancer and stroke. As such, much attention has 
been given to the development of diagnostic tools that would allow one to assay their 
activity in living tissues. Protease activity is regulated at many levels including 
transcription, translation, activation, and inhibition and in order to derive the maximum 
prognostic benefit, it is essential to study their activity within this complex environment. 
Initial attempts to accomplish this goal involved the use of organic fluorophores pairs that 
utilize Fluorescence Resonance Energy Transfer (FRET) but suffered many drawbacks. 
Quantum Dots (QD) have addressed many of the drawbacks of organic fluorophores in 
various optical imaging applications. These include a decreased sensitivity to 
photobleaching and chemical degradation, size-tunable narrow emission peaks, and broad 
absorbance allowing excitation of multiple peak emission QD by one excitation source. 
In this work, we propose to utilize Quantum Dots (QD) linked to gold nanoparticles 
(AuNPs) by protease cleavable peptide sequences to serve as probes for assaying protease 
activity both in vivo and in vitro. This work involved the synthesis and characterization 
of the various components necessary for the probe design as well as the optimization of 
probe characteristics to achieve highly biocompatible probes that exhibit both a high level 
of quenching and maximum fluorescence recovery in the presence of protease. Probe 
functionality was optimized and it was determined that probes with AuNP:QD ratio of 
10: 1 and peptide linker length of 6.5 nm resulted in highest and most linear fluorescent 
signal gain. The ability to multiplex probes was also validated by developing spectrally 
orthogonal probes sensitive to collagenase and cathepsin K. Our design is expected to 
have many applications in the research and understanding of the role of proteases in 
disease and as a predictive tool for the prognosis of diseases such as cancer. 
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Chapter 1: Introduction 
1.1. Enhanced Diagnostics 
1.1.1. Introduction 
In recent times, advances in many fields of biological research has opened the 
door for innovative treatments of various diseases. In addition, these same advances have 
allowed us to adopt a more systematic approach to medicine. Rather than having to wait 
for sytnptom onset and proceeding to generic treatment, personalized medicine aims to 
use these advances to tackle disease detection, screening, diagnosis, prognosis, and 
prediction on a more individualized basis. These various intervention points can be seen 
in Figure 1. 
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Figure 1 - Points of Intervention for Personalized Medicine 
From Myer et al. 2002 1 
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In many diseases, such as cancer, where the choice of treatment and variation in 
disease characteristics varies greatly from person to person, there is an especially 
important need to develop predictive markers for patient response to treatment. This 
need for predictive markers is highlighted by the fact that there are 2.2 million 
hospitalizations and over 100,000 deaths a year due to harmful drug reactions and side-
effects2. The ability to personalize treatment on the basis of an individual's specific 
disease state would greatly help reduce this number. 
This is especially vital to cancer as the therapeutic choices, which have become 
more aggressive over the last 20 years3, are linked to quite undesirable side effects4•5• 
Furthermore, many new therapies, such as imatinib, gefitinib, and cetuximab are effective 
only in cases where specific molecular markers are expressed at sufficient levels6• While 
work is being undertaken to develop diagnostic tools for all stages of cancer care, much 
attention is being given to the need to develop prognostic and predictive markers to guide 
treatment. An example of such markers is the family of cysteine cathepsins and their 
endogenous inhibitors. It has been shown that the activity of cysteine cathepsins is up-
regulated in invasive cancers due to a disruption balance between cathepsins and their 
inhibitors. Thus, cathepsin activity has been shown to be a good marker for survival 
length, relapse risk, and mortality and as such their ability to guide cancer therapy has 
been studied7. Also of note are estreogen receptor (ER) and a surface-bound receptor 
tyrosine kinase (Her2/Neu,), presence which guide the use of tamoxifen and 
trastuzumab 6• 
This need for prognostic and predictive markers ranges well beyond cancer. In 
Rheumatoid arthritis, where an increasing number of therapeutic choices have become 
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available, methodologies for predicting patient response have become more and more 
crucial. This is heightened by the high cost and the known side-effects of the various 
treatments8• Finally, the field of pharmacology is in dire need of markers for 
determining the pharmacokinetic, pharmacodynamic, and idiosyncratic response to 
various drugs9• As one example of this need, a recent study has shown that various 
factors can easily result in 600-fold differences in drug plasma concentrations in 
individuals of the same weight on the same dosage10. This is particularly important in the 
area of. cancer research, where proteolytic activity can highly affect drug distribution. 
1.1.2. Important Markers for Disease Diagnosis 
Having seen the need for prognostic and predictive indicators in disease, attention 
must be given to identifying such markers. Initial research in this field began as the 
understanding that genetic variability was linked to disease response and progressionu. 
In 1959, before the development of the modem genetics era, the field of pharmaco-
genetics had already been proposed12. The completion of the Human Genome project in 
2003 13, helped propel the field of genomics even further. Since then, work to identify 
biomarkers has expanded from the realm of genomics to include proteomics and 
degradomics. 
Efforts in the area of genomics have focused mainly on Single-Nucleotide 
14 . 15 . 1 k 16 d t t' . Polymorphisms , gene-expresswn patterns , oncov1ra mar ers , an mu a wns m 
mitochondrial DNA17• Similar efforts in the field ofproteomics are working towards the 
. d k fi . 'd' th 18,19,20 development of proteom1c profiles an mar ers or use m gm mg erapy . 
Particularly important to our proposed work is the area of degradomics or study of 
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proteases, their inhibitors, and substrates. This area, which in recent years has received 
more and more attention, uses the activity of proteases as markers for determining disease 
severity and allowing better prognostic and predictive diagnosis for patients. Many such 
proteases have been identified including urokinase plasminogen activator, cathepsins B, 
D, and L, as well as various matrix metallo-proteases21 .22• 
1.2. Proteases 
1.2.1. Background 
Proteases represent one set of markers that provide great promise as prognostic 
indicators of disease progress in cancer and other pathologies. As such, the proposed 
work focuses on providing a methodology for assaying their activity in living tissues. 
Proteases are a class of enzymes that result in the hydrolysis of peptide bonds in both 
proteins and polypeptides. Initially discovered as gastric enzymes involved in 
degradation of dietary proteins, they have since been defined as playing a key role in 
various cellular and biological functions23 . These include but our not limited to bone 
formation, homeostatic tissue remodeling, cell signaling and migration, wound healing, 
angiogenesis, apoptosis, digestion, cellular proliferation and differentiation, and 
fertilization23•24•• Currently, 460 different proteases have been identified as part of the 
human genome with an additional 93 inactive homologue which are thought to be 
involved in protease regulation/inhibition25. These numerous proteases belong to five 
main families: aspartic, metallo, cysteine, serine and threonine proteases. Figure 2 shows 
the distribution of the human proteases and their cellular localization. 
Human 
273 
Extracellular 
277 
Intracellular 
Figure 2 - Protease Families and CeUular Distribution 
Modified from Overall et al. 200726 
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These families use either covalent or acid-base catalysis to perform their 
hydrolytic function. The specificity of a given protease is defined by what sequences of 
peptides can be recognized by its active site. Figure 3 demonstrates the two forms of 
catalysis used by proteases and their binding to specific peptide sequences. 
a 
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fts. Thr protease) 
terminus 
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~ Hydrogen bond 
- - - Extension o substrate chain 
General acid-base cata ysis 
(Asp. metalloproteinases) 
Figure 3- Protease Hydrolytic Mechanism and Binding. 
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Modified from Turk et a!. 200652 
While some of these proteases have specifically defined functions, most are 
involved in intricate webs or cascades of cellular events. This intricate balance of 
proteolytic activity is maintained by protease specificity, the presence of inhibitors, 
presence of peptide substrate, and protease activation. As they function to cleave bonds 
in various proteins and enzymes, they are involved in regulating many biological 
processes both intracellularly and in the extra-cellular matrix (ECM). Serving such a 
crucial role in so many biological functions, it is evident to see how any disruption of 
their function can lead to and be a marker for various pathologies. 
1.2.2. Role of Proteases in Disease Progression 
Proteases play an important role in many pathologies. In some of these diseases, 
the level of proteolytic activity can serve as a marker for specific disease state and 
progression, while in others an understanding of the role of proteases can help guide the 
development of treatment options. 
Cancer, being a disease with such varied genetic causes, is one that would benefit 
greatly from the diagnostic insight that could be gained from protease activity. While all 
five families of proteases have been shown to play important roles in cancer development 
and progression, much of the research in relation to cancer has focused on one family of 
proteases, matrix-metallo proteases (MMPs). The up-regulation of MMPs in various 
forms of cancer is usually associated with poor prognosis27• Initial research into the role 
of proteases in cancer focused on their ability to degrade the ECM and thus facilitate both 
tumor growth and metastasis28• Since then, proteases have been increasingly implicated 
in all six hallmarks of cancer as defined by Hanahan et at29.: self-support in growth 
TGF-J3 
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signals, insensitivity to growth-inhibitory signals, escape from apoptosis, infinite 
replication, sustained angiogenesis, and tissue invasion and metastasis29. A summary of 
the roles of MMPs in these 6 hallmarks is given in Figure 4. 
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Figure 4 - Role of Pro teases in 6 Hallmarks of Cancer 
From Egelbad et al.30 
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The involvement of proteases, and MMPs in particular, in cancer cell growth is 
realized primarily by their ability to alter the availability of growth factors by releasing 
both membrane-bound growth factors3 l and the sequestered growth factors that are bound 
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to ECM components32• In addition, alterations of ECM components by increased MMP 
activity has been shown to affect ECM-cell signaling33• Proteases are also involved in 
allowing cancer cells to evade apoptosis through the down-regulation of apoptotic 
"nh"b" h 34 1 1 1tors sue as MMP-3 and Caspase-1 . Proteases are further involved in cancer 
progression by inhibiting the body's immune response. This is accomplished by their 
ability to inhibit T-cell proliferation35, activating TGF-(3 which inhibit T-lymphocytes36, 
and increasing cancer-cell resistance to the immune system37• 
Angiogenesis, another crucial component of cancer development, is enabled by 
the increased activity of many proteases. Over-expression of MMP-2, which acts to 
cleave collagen type IV, leads to the exposure of a avf33 integrin-binding site and 
promotes tumor growth and angiogenesis38• MMP-9, which also has heightened activity 
in many cancers, plays a crucial role by leading to an increase in VEGF39• Finally, 
MMP-14 degrades the pericellular fibrin matrix surrounding vessels and allows 
endothelial invasion and outgrowth40• 
Finally, and most relevant to our proposed work, is the role of proteases in 
degrading ECM and thus promoting tumor invasion and metastasis. Three main systems 
of proteases have been heavily researched for their involvement in tumor metastasis, the 
serine protease urokinase-type plasminogen activator (uP A), the cysteine proteases such 
as cathepisn B, and MMPs. uP A has been showed to directly affect a cancer cells 
potential for invasion41 • Many of the cathepsins have been shown to mark the transition 
to tumor invasiveness and malignancy and have been shown to be an indicator of 
metastatic potential42• The role of MMPs has also been greatly studied. These protease 
enable metastasis by activating cell-migration signals43, promoting cell detachment from 
the ECM by cleaving CD4444 and E-cadherin45, and enabling intravasation of cancer 
cells into the blood stream46• 
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In addition to the roles proteases play in disease progression, it is important to 
understand how their expression and activity is regulated. Although cancer cells 
themselves are responsible for the increase in activity of certain proteases, their influence 
on protease secretion of stromal cells is equally if not more important. The mechanism 
by which cancer cells alter the expressions in their surrounding stromal cells is thought to 
involve secretion of interleukins, interferons, emmprin and growth factors47• This is 
important to keep in mind when developing in vitro models of cancer protease activity. 
To conclude, as proteases play such a crucial role in cancer progression and have been 
linked to tumor aggressiveness and to the likelihood of recurrence, protease activity can 
provide an important marker in the determination of optimal patient treatment. 
In addition to cancer, proteases play a great role in various other diseases. In 
Multiple Sclerosis, proteases are involved in many of the stages defining the disease 
including demyelination, apoptosis, axon injury, and various elements of the 
inflammatory response involved48. Protease activity can thus be used as a target for 
developing treatments as well as being able to identify various stages of the disease 
progression. 
In HIV, proteases play a big role in the spread of the virus by driving ECM 
degradation and allowing for the spread of the virus and granting it access to immuno-
privileged locations in the body49• Proteases also play a role in many respiratory 
pathologies including allergies in which they play a great role in activating PAR-2 
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receptors50. Finally, a great deal of genetic disease exist that are as a result of over-
activation or a deficiency in protease activity. 42 such disorders have currently been 
identified51 which result in a variety of symptoms sparming over all major organs in the 
body. This wide range of disorders further goes to show the diversity of roles that 
proteases play in homeostasis. 
1.2.3. Protease Regulation and Activation 
The regulation of protease activity is a complex process involving protease 
production, activation, and inhibition. Proteases are generally produced as zymogen 
precursors in inactive form. The first level of cellular control is variation in transcription 
of the mRNA encoding these precursors and their translation into these inactive 
zymogens. Once present, the activation of these precursors presents the second level of 
regulation. This activation commonly occurs through the cleavage of C-terminal pro-
peptides52. This activation occurs through one of three mechanisms: autocatalysis, 
activation by other proteases, or through the mechanism of an activation complex. 
Having been activated, proteolytic activity is further regulated by the presence of 
inhibitors and cofactors. Inhibitors, which have been classified into 18 main families, 
operate by competing for and binding to the active sites of proteases25 . These inhibitors 
are themselves regulated by the presence of co-factors which can reversibly bind and 
affect their function. Figure 5 demonstrates a simple view of protease regulation post-
translation. 
Zymogen 
~ 
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Figure 5 - Regulation of Protease Activity Post-Translation 
From Turk et al. 200651 
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The complex homeostatic balance created by these various control mechanisms 
produces a challenge to many genmnic and proteotnic approaches used to diagnose 
pathologies. While the regulation of protease levels plays a role in disease states, it is the 
over or under-regulation of proteolytic activity that is the greatest concern. As such, 
methodologies are required that can accurately assay such activity. 
1.2.4. Protease Kinetics 
The study of protease activity can be done in two fashions. The first is to try to 
profile the function of individual pro teases 52. The second is to study the cleavage of 
substrate particles. In both cases, an understanding of the kinetics involved is essential to 
the quantification and modeling of observed results. 
The model commonly used to describe protease cleavage of peptide substrates is 
that of Michaelis-Menten kinetics53•54'55 '56• The Michaelis-Menten model, initially 
proposed by Leon or Michaelis and Maud Men ten in 1913 57, describes the rate at which 
an enzyme with an excess of substrate catalyzes the product in question. The reaction 
being described can be seen below: 
E+S 
12 
In this model, E describes the enzyme (protease) concentration, S denotes the 
substrate (peptide to be cleaved), and P denotes the products (cleaved peptides ). Analysis 
of this model leads to the following equation58 that describes the velocity of the reaction: 
In this equation V denotes the velocity of the reaction, V max denotes the maximum 
velocity of the reaction, and Km (Michaelis Constant) is the concentration of substrate at 
which the reaction proceeds at half its maximum velocity. These parameters can be seen 
in visual format in Figure 6 and are usually determined experimentally by exposing the 
enzyme to varying levels of substrate. 
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Figure 6 - Typical Graph of Cleavage Rate vs. Substrate Concentration used to calculate Michaelis-
Menten Parameters 
1.3. Probes for Protease Detection 
1.3.1. Overview 
Various approaches have been taken to the development of methodologies to 
assay protease activity. These various efforts can be broken down into two categories, 
each with distinct goals. The first is methodologies that have been developed for the 
purpose of research and in vitro applications. These have focused understanding protease 
function, identifying important protease markers in disease, and screening for protease 
substrates. The second set of methodologies is aimed at developing probes for in vivo 
detection and imaging. These approaches are based on translating protease activity into 
some form of optical signal and are designed to better understand protease function in 
vivo and act as prognostic and predictive markers for pathologies. 
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1.3.2. In Vitro Protease Detection 
Focus in this area can be broken down into three levels: work at the 
transcriptional level, work at the protein level, and work at the protease activity level. 
Although the first two levels of detection play a role in the discovery of protease 
function, it is really the activity in living tissue that is important. As has been mentioned, 
many levels of protease control are post-translational. As such, determining the activity 
and not just presence of proteases in living tissues is of the greatest importance. 
At the transcriptional level, much of the advances have focused on the 
development of DNA micro-arrays. The identification of protease coding genes25, 
facilitated by the sequencing of the human genome, has led to micro-array platforms such 
as the Hu/Mu Protln Microarray59 and the CLIP-CHIP60• These both rely on extracting 
RNA from the tissue in question, amplifying it, and hybridizing it with the microarray. 
Further analysis can be done with quantitative real-time polymerase chain reaction61 • 
This work, however, is limited in its scope as it is only able to assay protease activity 
very indirectly. While allowing the detection of various mechanisms that alter 
transcription, such as genetic mutations in promoter sequences, this provides only a 
limited view of the various levels of protease control. 
At the proteomic level, much of the efforts have focused on the use of mass-
spectroscopy techniques62 to achieve high throughput screening. In these systems, 
complex protein samples are separated by chromatography. These are then ionized using 
electrospray ionization or matrix-assisted laser desorption/ionization (MALDI) and 
analyzed by combinations of Time of Flight (TOF), ion trapping, and quadripole 
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analyzers. One such example is MUltiDimensional Protein Identification Technology 
(MUD PIT) which was proposed by Link et al63 • While providing an improvement over 
methods that assay only transcription, these methodologies are also limited in their ability 
to assay protease activity. Many proteases that play important roles in cancer progression 
are naturally present and stored both in the cellular and ECM environment. It is changes 
that result in their activation and in the disruption of their inhibitors that allow protease 
activity to change. 
Finally, various efforts at the cellular level have been made to survey activity. 
One example is the use of flow cytometry to measure cathepsin activity in cells64• 
Another technique that has been used involves the introduction of probes in plasmid 
vectors into cells. One group utilized such a technique to monitor MMP activity by 
creating a probe containing DsRed2 and cyan fluorescent protein (CFP) linked by and 
MMP substrate site65 while another used a similar technique to study the role of 
ubiquitin66• 
1.3.3. In Vivo Fluorescent Probes 
As demonstrated by the limitations of the methodologies surveyed in section 
5.3.2, there is a great need for the development of probes that will allow in vivo analysis 
and imaging of protease activity, an indicator affected by all four levels of protease 
control. These techniques are essential as they allow determination of protease activity 
affected not only by its presence but also activation, localization, and inhibition. There 
are two main groups of such probes, those that detect active proteases and those that 
monitor protease substrate cleavage. Both approaches rely on the principle of 
16 
Forster/Fluorescence resonance energy transfer (FRET). Named after Theoder Forsrter 
in 1948, it describes the transfer of energy from one chromophore to another when they 
are in close proximity67. The level of energy transfer is defined by the spectral overlap of 
the emission of one fluorophore and absorbance of the other as well as their spatial 
separation. A visual representation of this effect and how it affects a sample emission 
spectra as well as the equation describing the level of energy transfer can be seen in 
Figure 7. In the equation below, E denotes the FRET efficiency (fraction of energy 
transferred), r is the distance between the two molecules, and Ro is the Forster distance 
(distance at which 50% of energy is transferred). 
no FRET FRET 
Figure 7- Forster/Fiuorescence Resonance Energy Transfer 
From Rudolf et at. 200368 
The first set of probes built on this principle is activity based probes69• They are 
generally made up of three parts. The first is a reactive 'warhead' that covalently bonds 
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itself to a target in question, namely an active protease in this case. This is 
complemented by a peptide that increases the binding specificity of the probe. The final 
component is a fluorophore and quencher pair. Once the probe attaches itself to the 
target, a reaction is catalyzed that releases the quencher. This results in an increase in 
fluorescence which can be measured and correlated to the level of active protease. The 
general design of these probes can be visualized in Figure 8. This technique has been 
widely applied for the detection and in vivo imaging of various proteases including 
cathepsin, MMP activity70•71 '72 . 
Peptide 
Probe 
Figure 8- Activity Based Probe Design -When the reactive 'warhead' of the probe attaches itself to the active 
site on the protease, it results in the release of the quencher and thus restore the fluorescence of the probe. The 
specifity of the probe is increased by the presence of a peptide. 
From Kato et al. 200571 
The second group of probes is those that rely on measuring protease substrate 
cleavage and are the most relevant to our proposed work. This class of probes also relies 
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on FRET and involves the use of three main parts. They consist of a fluorophore and a 
quencher linked by a cleavable peptide substrate. When these probes are exposed to an 
active protease that recognizes and cleaves the peptide substrate, the quencher and 
fluorophore separate and fluorescence increases. This can be visualized in Figure 9. 
Intact Probe: 
Fluorescence Quenched 
Protease Cleavage of 
Specific Peptide Substrate 
Figure 9 - Principles of FRET protease probes 
Separation of 2 parts: 
Fluorescence Restored 
The choice of fluorophore and quencher varies based on the application. Several 
such combinations that have been used are tryptophan with dinotrophenyC3, 
dinitrophenyl with methoxycoumarin74, EDANS with DABSYL75, and CyDye pairs such 
as Cy3 wih Cy5Q quencher76. A great deal of the functionality of the probe relies on the 
specific recognition and cleavage of the peptide sequence by the protease in question. 
As such, much attention has been given to identifying and profiling the specificity of 
various sequences to various proteases. An example can be seen in the development of 
peptide microarrays used to determine specificity77 . These techniques have been shown 
to be useful not just in vitro but also for in vivo imaging of protease activity in various 
pathologies such as tumors78'79 and myocardial infractions80. 
1.3.4. Limitations of Substrate Based Probes using Organic 
Fluorophores 
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Probes using organic fluorophores and quenchers suffer from a set of fundamental 
limitations. The first is that organic fluorophores and quenchers are sensitive to both 
photobleaching as well as chemical degradation81 • As these probes are designed for 
monitoring and quantify protease activity in vivo, this can be a severe limitation. In order 
to try and avoid photobleaching, experiments using these probes must be done in short 
time frames. In addition, as the degree of photobleaching is hard to determine, 
quantification of protease activity is next to impossible. 
In addition, the narrow absorption and wide emission spectra of organic 
fluorophores makes the use of multiplexed experiments difficult81•82• Such experiments 
would require multiple excitation sources and quantification of results would be made 
very difficult due to spectral overlap of emission spectra. It is these challenges that our 
proposed work is designed to address. 
1.4. Quantum Dots 
1.4.1. General Overview 
Quantum Dots (QD) are a class of nanoparticles that have recently emerged as a 
very promising solution to many biological problems83•84•85 • QD, which are semi-
conductor nanocrystals, operate on the principle of quantum confmement. In bulk semi-
conductor materials, electron-hole pairs are bound by the Bohr exciton radius. QD, 
which range from 2 to 10 nm in radius, further restrict the electron-hole pairs leading to 
unique optical and electrical properties. QD absorb photons of light anywhere at or 
20 
below their first absorption peak and release the energy in excitonic fluorescence. The 
position of this sharp emission peak on the spectrum is tunable and dependent on the size 
of the QD. Figure 10 demonstrates the various the absorption and emission spectra for 
particles of various sizes. It is these unique optical properties which give QD many 
advantages in biological applications and make them ideal for the proposed work. 
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Figure 10- Absorbance and Fluorescence of QD of various sizes 
Modified from Portney 200686 
QD are generally composed of elements from the periodic groups II- VI (such as 
CdSe, CdTE) or 111- V (such as InP). 87 While this semiconductor crystals provide the 
effects described above, two modifications are required for use in biological systems. 
The first of these is the capping of the QD with a high band-gap material88•89 . This cap 
allows the quantum yield of the QD to be increased while simultaneously providing a 
layer of protection to the biological system from the toxic elements that make up the core 
crystal. In addition to a cap, QD require a water solubilization coating which both further 
protects the QD and allows the use of QD in aqueous environments90 . 
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1.4.2. Advantages of Quantum Dot 
The unique properties of QD present many advantages over organic fluorophores 
in designing a system to monitor protease activity. The first of these is the ease of 
creating a system of probes with orthogonal emission peaks that can easily be 
differentiated. QD have sharp emission peaks whose positions are easily tunable. In 
addition, the existence of multiple energy states in QD allows them to be excited at any 
wavelength below the absorbance peak87• In comparison, organic fluorophores generally 
possess broader emission spectrums with a long tail at red wavelengths. In addition, the 
excitation spectrum for organic flurophores is generally very narrow. Thus, a system 
utilizing QD would need only one excitation source, allow numerous proteases to be 
studied, and would produce readings that could easily be quantitatively analyzed. The 
use of organic fluorophores would however necessitate multiple excitation sources and 
possess limited multiplexing ability. 
The second major advantage QD present is their greatly decreased sensitivity to 
both photobleaching and chemical degradation91'92• Conventional organic fluorophores 
are very sensitive to photobleaching and as such are not suitable for long-term imaging. 
This can be seen in Figure 11. In addition, properly coated QD are protected from 
chemical degradation in harsh salt conditions (0.01 to 1 M), a wide range of pH (1 to 14), 
and even after harsh treatment with 1.0 M hydrochloric acid93 • 
lO 40 60 80 100 uo 140 160 180 
'fime(s) 
Figure 11 • Photo bleaching Resistance of Quantum Dots 
From Alivlsatos et al. 200587 
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The third major advantage of QD for our application is that of their size. The 
range they are in allows for multiple fluorescence quenchers to be attached to each 
particle. In addition, their bigger size with respect to organic fluorophores allows for 
better control over their cellular distribution. QD have been shown to behave much like 
fluorescent proteins and do not suffer from any limitations in terms of steric hindrance or 
binding kinetics94• In addition, due to their intermediate size range, QD are small enough 
to reduce reticuloendothelial uptake and phagocytic opsonization while being large 
enough to avoid renal filtration95 • Finally, due to their size, QD can accumulate in tumor 
tissues with passive targeting through the enhanced permeability and retention effect96• 
1.4.3. Various Types of Quantum Dots and choice of CdSe 
As discussed earlier, QD can be made with pairs of various elements in the 
periodic groups II-VI or III-V. Examples of these include but are not limited to CdS, 
CdSe, CdTe, PbSe, InP, and CdHgTe. While these QD possess similar properties they 
vary mainly in the size-dependence of their emission peaks. This size dependence can be 
seen for various types in Figure 12. 
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Figure 12- Various Types of Quantum Dots and their Size Dependant Emission 
From Michalet et al. 200589 
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The choice of which of these particles to use is based on the application that is 
needed. Figure 13 overlays the spectra of various forms of QD with various biological 
applications. Monitoring protease activity in vivo at depths great than 500 ~--tm requires 
the use of NIR light in the 650-950 nm range97. This constrains the choice of QD for our 
application to CdSe and CdTe QD. Of the two, CdSe have the advantage of being also 
found in the visible range. This allows initial characterization and in vitro studies to be 
undertaken with greater ease. 
In addition to spectral considerations, the level of research in terms of synthesis 
strategies and cytotoxicity must also be considered. The various synthesis strategies that 
have been developed for water-solubilization and that have shown promise in various in 
vivo applications have mainly involved the use of CdSe QD. Likewise, evaluation of QD 
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cytotoxicity has focused on CdSe QD. As such, all efforts will involve the use of 
CdSe QD. The development of probes further into the NIR range could eventually be 
done by using the CdTe QD. 
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1.4.4. Water Solubilization of Quantum Dots 
PbSerre 
.,. 
The use of QD in biological applications necessitates the use of some form of 
water solubilization. This coating has three main tasks. First it allows the QD to be 
soluble in biological aqueous environments. Second it provides further protection to the 
QD against degradation improving cytotoxicity. Finally, it provides a scaffold that can 
be used to further functionalize the particle. In addition to these basic properties our 
proposed work requires that the coating be thin enough to allow quenching of particle 
fluorescence and at the same time maintain the full fluorescence of the particle. 
Many techniques have been employed to achieve this purpose. These fall into 
three main categories. The first of these is surface-ligand exchange. In this group of 
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methodologies, the TOPO coating of QD is replaced by bio-compatible ligands. 
Examples of these include the use of mercaptocarbonic acid98, mercaptoacetic acid99, 
bidentate ligands100, and dihydrolipoic acid derivatives. 101 The drawback to most of these 
methodologies is that the surface exchange usually results in a decrease in the quantum 
yield of the particles and thus counteracts one of the benefits of using QD. 
The second general strategy for solubilizing QD is to create silica shells that act as 
an insulation. Various groups have demonstrated these techniques with the use of 
mercaptopropyl silanols92•102 and tetraethyl orthosilicates103• While these show great 
stability and even enhance fluorescence, they have one main drawback for our 
applications. The size of the shells being produced has a thickness of 5-30 nm. This size 
of the resulting QD greatly limits their application as quenchable particles since 
quenching of fluorescence varies with separation of the quencher and fluorophore. 
The third main group of strategies is the use of amphiphillic polymers which coat 
the surface of the QD. These strategies rely on a tight encapsulation of the QD by the 
polymers due to hydrophobic interactions. The resulting QD are composed such that the 
hydrophobic portion of the coating tightly interleaves with the TOPO coating and leaves 
the hydrophilic outer groups on the outside to allow solubility in water and further 
functionalization. Various strategies have been employed including amphiphillic 
triblock copolymers104, poly(maleic anhydride-alt-1-tetradecene) (PMA0)105, 
amphiphillic sacharides106, and a modified acrylic acid polymer107• These strategies have 
the advantages that they produce a rather thin coating, do not affect QD fluorescence, and 
can easily be functionalized. For these reasons, this class of water solubilization will be 
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chosen for the proposed work. Work will mainly focus on the use of the amphiphilic 
triblock copolymers as well as PMAO. 
1.5. Imaging of Quantum Dots 
1.5.1. Overview 
Due to their many benefits, a great deal of attention has been focused on the 
utilization of QD for in vivo and in vitro optical imaging. This work has helped to 
identify some of the characteristics that defme the behavior of QD in biological 
environments. These will be important to understand and build upon in the proposed 
work. 
1.5.2. In Vitro Imaging 
In vitro imaging of cells has focused on two main areas. The first is the 
development of QD for the labeling of cell-surface receptors. This has allowed study of 
the function, internalization, and distribution of various membrane receptors including 
the ErbB/HER receptor protein-tyrosine kinase108, glycine receptors109, and integrins110. 
An overview of the methodologies used for this type oftargeting can be found in Jaiswal 
et al. 111 and imaging in these works was conducted with both confocal and 
epifluorescence microscopy. 
The second area of focus of in vitro imaging of QD has been developing 
methodologies for their intracellular delivery. Initial attempts hoped to take advantage of 
. d . 112 passive en ocytos1s . Although somewhat successful, the resulting QD remained 
localized in vesicles. Other attempts were made at using membrane-receptor signals to 
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induce uptake113• This was shown to occur by activation of signaling pathways and 
also indirectly by increasing the QD concentration near the surface of cells. Two 
alternative techniques, micro-injection114 and electroporation115, have also been studied. 
While micro-injection has been shown to be quite successful, having been able to 
encapsulate over 4x109 QD per cell, this technique is limited as it requires cell by cell 
processing. 
To achieve more direct uptake, another set of efforts has focused on using 
peptides directed at the twin-arginine translocation (Tat) pathway. This methodology, 
which results in macropinocytosis116, has been studied using spinning dark confocal 
microscopy to follow the QD post uptake117. A lot of the above mentioned methods 
result in the accumulation of QD in cellular vesicles. As such, a final set of attempts has 
used polyethylenimine-PEG as an endosome-disrupting agent to allow cytoplasmic 
distribution ofQD 118• 
1.5.3. In Vivo Imaging 
More relevant to our work is the use of QD for in vivo imaging. This work 
demonstrates some of the challenges and components that must be considered when 
utilizing QD for in vivo imaging. One of the initial in vivo applications of QD was in a 
frog embryo model by Dubertret et al. 119. It was shown that with the use of proper water 
solubilization protective coatings, QD could be used to image embryo development for 
up to four days with no cytotoxicity. Following this success, several groups have 
reported successful use of QD in mouse models. The work of Ballou et al. demonstrated 
general behavior of injected QD in live mice including circulation times and tissue 
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distributions using both whole-body imaging and microscopy of tissue samples 120• 
Subsequently, Voura et al. utilized QD in order to track metastatic tumor extravasation in 
vivo12 1. Though this demonstrated the utility of QD in understanding in vivo behavior, 
imaging of these specimens was performed after the sacrifice of the animals. 
One of the first successful demonstrations of QD for in vivo imaging and 
detection of tumors was performed by Gao et al.96 In this paper, they demonstrated the 
utility of QD to successfully image tumors in vivo. Two forms of tumor targeting were 
investigated as seen in Figure 14. The first was passive tumor targeting in which QD 
accumulate in the tumor solely by the EPR effect. The second, active targeting, involved 
the conjugation of the QD to cancer specific antibodies (Prostate-specific meinbrane 
antigen PSMA). These antibodies, which are conjugated onto free COOH groups of the 
amphiphilic polymer coating, help to increase tumor QD accumulation by allowing the 
QD to rapidly binding to tumor-specific antigens. 
Figure 14 -Active and Passive Targeting of QD 
Modified from Gao et al. 200496 
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The results of tail veil injections on the biodistribution of the QD were 
examined as seen in Figure 15. In section a, QD-COOH and QD-PEG were injected at 6 
nmol via tail vein and images are after 24hrs, while QD-PSMA were only injected at 0.4 
nmol and imaged after 2 hr. Section b shows results when all three groups were injected 
at 0.4 nmol and imaged after 2 hr. As can be seen by the tumor images in section a, 
tumor accumulation was heightened by active targeting. This is shown by the fact that an 
injection of 1115 as many targeted QD produced a better image after 2 hr than did only 
PEG-coated QD after 24hr. Of interest, however, is the fact that even at 2 hr, passive 
targeting of QD did produce some signal in the tumor as seen in section b. 
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Figure 15- Biodistribution of QD in various tissues -Green represents tissue autofluorescence while red 
represents signal from QD. Images are of 5-10 ~m sections taken with epifluorescence microscopy. 
From Gao et al. 200496 
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In addition to the ability to determine biodistribution in the n1ice, whole-body 
imaging was performed and demonstrated the ability to detect tumor location as seen in 
Figure 16. 
Figure 16- Whole-Body Imaging to Detect-Tumor Location - Panel a represents the original picture 
taken. Using spectral unmixing algorithms, mouse autofluorescence, panel b, and QD signal, panel c, were 
separated. Panel d represents the overlap of mouse autofluorescence (yellow) and the tumor (orange). 
From Gao et at. 200496 
This work demonstrated the ability to get QD accumulation in the tumor, whether 
through passive or active targeting, and visualize them using whole-body imaging, laying 
the foundation for the in vivo studies in the proposed work. 
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1.6. Protease Probes using Quantum Dots 
1.6.1. Overview of Quantum Dot attempts 
QD are currently being investigated in a variety of biological applications 
including small molecule biosensors, measuring peptide-RNA interactions, and targeting 
cell surface receptors122. Directly relevant to the proposed work, initial attempts have 
been made to utilize QD for the monitoring of protease activity123•124•125•126• The general 
design for the various probes has been similar in nature. A Cd/Se QD is used as a 
fluorescence source and is rendered water soluble. A degradable peptide linker is then 
used to attach some form of quenching molecule. 
The various approaches described above vary mainly in three aspects. The form 
of water solubilization used, the choice of quencher molecule, and the linker used. The 
various water solubilization methods that have been used are DHLA126•124 and 
streptavidin125• The quenchers they chose to use were rhodamine124, Cy3, and dark 
quencher QXL-520. These attempts have been successful at demonstrating the utility of 
this form of probe. 
1.6.2. Quantum Dot Quenching with Gold Nanoparticles 
As an alternative to the use of organic quenchers, the proposed work chooses to 
use AuNPs to obtain quenching. Many groups have shown the ability of AuNPs as 
quenchers for organic dyes127• In addition, recent work has shown that AuNPs can serve 
as optical quenchers for QD128• Figure 17 demonstrates the quenching ability of just one 
AuNP linked to a QD. 
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Figure 17- Optical Quenching of QD by a gold nanoparticle- Histograms of the intensity within the QD 
for both gold-quenched (seen in black) and unquenched (seen in gray). Pictures were taken using 
epifluorescence microscopy of QD adsorbed onto a glass surface. 
From Gueroui et al. 2004 128 
1.6.3. Initial Work 
Two groups have successfully demonstrated at a proof of principle level the 
quenching of QD with AuNPs 129' 130. In 2005, Chang et al. assembled a QD protease-
activated probe 129. The general functionality of the probe can be seen in Figure 18. 
QD-peptide-Au NP 
Quenched Fluorescence 
Protease Attack 
Peptide Cleavage 
Q 
Q 
Restored Bright Fluorescence 
Qf QD's as AY.~ leave 
Figure 18 - Protease-activated Quantum Dot Probe 
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This work utilized Cd/Se Cd/S QD coated with a PMAO water solubilization 
coating. This PMAO coating was further functionalized by the addition of poly( ethylene 
glycol) to increase water solubility and stability. The resulting QD were then conjugated 
to a degradable peptide sequence GGLGPAGC. Mono-maleimide functionalized AuNPs 
were then attached to the QD via the cysteine residue on the conjugated peptide. A 
control group was also created in which all steps were carried out except for AuNP 
attachment. An initial study demonstrated that the protease-activated probes had been 
quenched by 71% as can be seen in Figure 19. 
Figure 19- Quenching of QD by AuNP 
From Chang E. et al. 2005.129 
This demonstration was followed by a study to determine the ability of the probes 
to regain their fluorescence upon exposure to collagenase. The results of this study can 
be seen in Figure 20. The probe was incubated with 0.2 mg/ml of collagenase and with 
water as a control. In addition, auto-fluorescence measurements were taken for 
collagenase to use as a baseline for fluorescence. The study showed a 52% recover of 
fluorescence at the 4 7 hr time point. 
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Figure 20- Qd Probe Fluorescence recovery - Fluorescence recovery due to peptide linker cleavage was 
measured in the presence of 0.2 mg/L collagenase in HBS and HBS control. Collagenase autofluorescence 
was also measured to calibrate against. 
From Chang E. et al. 2005.129 
In addition to this effort, Kim et al. also demonstrated the functionality of such 
QD - AuNP conjugates130. They utilized a similar approach and demonstrated its 
application as a multiplexed assay by conjugating the probes onto a surface. 
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1.7. Project Summary 
The development of a tool that would allow one to assay the activity of multiple 
proteases in real time, with ease of quantification, and in live tissue is a goal that holds 
great potential. QD, who possess both the stability and narrow emission peaks required, 
were used to create probes that held such promise. By linking the fluorescent QD to 
shield-like AuNP via protease degradable linkers, protease-activated quantum dot probes 
were fabricated. These probes, whose emission properties can easily be tuned via the size 
of QD used, are both stable and easily quantifiable. In the presence of active proteases, 
the linkers are cleaved, AuNP are released, and the QD fluorescence is restored. 
To construct an optimized probe, both linker length and AuNP:QD ratio were 
investigated to determine their effect on fluorescence recovery. Since both an increase in 
AuNP:QD ratio and decrease in linker length cause greater quenching (potential for 
recovery) while simultaneously decreasing protease access, an optimum balance needed 
to be found. 
Finally, with optimization complete, two probes with orthogonal emission spectra 
(sensitive to either cathepsin K or collagenase) were fabricated. It was demonstrated that 
one could use these two probes simultaneously to monitor proteolytic activity. 
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Chapter 2: Materials and Methods 
2.1. Synthesis of Poly( acrylic acid)-Oieylamine Water Solubilized QD 
Water solubilized QD required for production of the probes were synthesized by 
forming Cd/Se cores, adding Zn/S shells, and solubilizing these with a poly( acrylic acid)-
oleyl amine (P AA-OA) coating. These processes are outlined below. 
2.1.1. Cd/Se Core Synthesis 
Cd/Se Core synthesis was undertaken using a methodology previously reported by 
Li et al. 131 Before beginning the reaction a stock solution of 1: 1.2:2. 7 molar ratio 
Se(99.5%):tributylphosphine(97%):1-octadecene was prepared. The initial stage of the 
reaction involved 0.4 mmol of CdO (99.99%), 1.6 mmol of stearic acid (99%), and 4g of 
ODE in a 50ml 3-neck flask. This mixture was heated to about 180 °C or until the 
solution became clear. The solution was then cooled to room temperature. 
Then 1.5g of ODA (97%) and 0.5 g of TOPO (90%) were added. The 3-neck 
flask was filled with argon and heated to 280 °C. As soon as this temperature was 
reached, a volume containing 2 mmol of Se of the Se-TBP solution is injected. The 
reaction was terminated, resulting in a stop of growth in size of the QD, by pouring the 
resulting liquid into a solution of hexane or chloroform. Resulting particle size was 
controlled by varying the time in between Se injection and quenching of the solution, 
with 15s producing green QD to 3-4 min producing red QD. Initially, small reactions 
were undertaken with small withdrawals of the solution at various time intervals to 
determine the time-dependency of the size of the QD. With this determined, the entire 
batch was quenched at once at a given time point to produce large numbers of QD. 
These cores were then cleaned as outlined in section 2.1.3. 
2.1.2. Zn/S Shelling 
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In order to shell Cd/Se particles with Zn/S, QD concentration and size were 
determined. Particle size was obtained by measuring peak absorbance on a UV-Vis 
spectrophotometer between 400-800 nm. This absorbance spectrum was used to 
calculate size using standard curves published by Yu et al. 132 as seen in Figure 21 where 
the X-axis denotes the peak absorbance. 
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Figure 21 - CdSe standard Curve for Size vs. Peak Absorption 
From Yu et al. 2003131 
QD particle concentration was determined in two ways. The first method was to 
use the empirical fitting of concentration to absorbance as described by Yu et al. 132. In 
their model, A=eCL and e=5857(D/"65 which leads to C=AI(L*5857(D/"65). In this 
model A represents absorbance at peak, C represents concentration, L is the path length of 
the beam measuring absorbance, and D is the diameter of the QD. While this method 
yielded good estimations of concentration, more precise concentrations were obtained by 
performing Inductively Coupled Plasma with Optical Emission Spectroscopy 
(ICP/OES) as described in section 2.2.3. 
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Having determined size and concentration of QD, calculations were undertaken to 
determine the amount of reagents needed for each shelling layer. This calculation was 
made using the knowledge that each ZnS layer was approximately 0.35 nm. Based on the 
change in volume produced by each layer and the density of both Zn and S, amounts for 
each shell were calculated. Shelling of the particles was undertaken using the method 
described by Li et al. 133• 0.04 M solutions ofboth ZnO and S were prepared. ODA and 
ODE were added to the QD to be shelled, currently in hexane in a 3-neck flask. The 
solution was placed under vacuum and heated to 1 00 oc to remove the hexane. Once 
complete, the flask was placed under argon flow and heated to 200 °C. Once this 
temperature was reached, an injection of the volume required for the first Zn shell was 
added. To determine when to add the next layer, UV-Vis readings were taken until there 
was no longer a shift in the peak absorption. This was repeated until the QD were shelled 
with three layers. 
2.1.3. Cleaning of Cd/Se cores and shelled QD 
In order to accomplish the cleaning of the particles after both core synthesis and 
Zn/S shelling several methodologies were combined and modified. The final cleaning 
protocol involved two cleaning procedures performed one after the other. In the first 
stage, an equal volume of methanol was added to the hexane containing the QD. In the 
first few washes, the presence of various side products required centrifugation at 3000 
r.p.m. for 5 min. to achieve separation. The top hexane layer was collected and the 
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process was repeated several times until the precipitate decreased in quantity and had 
little fluorescence left. In addition, for maximum yield, the precipitates were themselves 
re-dissolved in hexane and undergo the same cleaning procedure to extract the majority 
ofQD. 
Once the hexane/methanol cleaning was completed, a further washing step was 
required. In the initial step an equal volume of ether was added to the QD currently in 
hexane. Ethanol was then added until flocculation was observed. The resulting mixture 
was then centrifuged at 3000 r.p.m. for 5 min yielding QD in precipitated form. The 
supernatant was taken off and discarded and the QD were re-suspended in chloroform. 
Again a 1: I :2 mixture of chloroform: ether: ethanol was made, and centrifuged. This was 
repeated until the precipitate three times. After the fmal centrifugation, the QD were 
stored in the chloroform for storage. 
2.1.3. PAA-OA Water Solubilization 
PAA-OA solubilization was performed using 5k PAA as described. PAA was 
reacted with oleylamine in chloroform overnight using EDC as an activator for the 
carboxyl group. The molar ratio of P AA:OA used was I: 10. Upon completion, a 
solution of QD was prepared in chloroform. The PAA-OA polymer was added at a an 
excess (over 100:1 PAA-OA:QD molar ratio) and was allowed to stir overnight. An 
equal volume of water was then added and the solution was vacuum dried using Rotary 
Evaporation (Rotovap) to remove the chloroform. The final product was centrifuged 
using an ultra-centrifuge at 200,000 g for 3 hr to remove excess polymer. 
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2.2. Characterization of Quantum Dots 
The trend in recent literature involving QD is to ensure adequate characterization 
of all stages of QD synthesis. This requires the determination of several key 
characteristics of the QD at each stage of the synthesis. Once cores are produced, their 
size, their concentration, as well as their absorbance and emission spectra must be 
obtained. Similarly, this must be repeated following QD shelling. The sections to follow 
describe the methods involved in determining each of these characteristics. 
2.2.1. Absorbance/Emission Spectra 
Absorbance spectra were captured on a Varian Cry300 Bio UV-Vis 
Spectrophotometer. The UV-Vis was first calibrated to the solvent in which the QD were 
suspended. Then absorption scans were taken from 400-800 nm. Emission spectra were 
collected for the particles using a SPEX FL3-22 Fluorimeter. QD were excited at 360 nm 
and emission scans were collected between 400 to 700 nm. Bandpass slits and 
integration time were set to 3 nm/3 nm and 100 ms. 
2.2.2. TEM Imaging: Determining Size 
Size of the QD particles was determined by TEM imaging of the cores, the 
shelled QD, and following water-solubilization. TEM images were taken with a JEOL 
2010 Transmission Electron Microscope. 
2.2.3. ICP/OES: Determining Concentration 
In order to determine QD concentration at the various stages of synthesis 
ICP/OES was used. 100 ~-tL ofQD were added to 400 ~-tL oftrace grade nitric acid. The 
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solution was stirred at medium speed and at 60 oc for five minutes until the solution 
goes colorless. The solution was then transferred to a volumetric flask and diluted with 
10 mL of MilliQ water. Standard solutions of 0, 1, 5, 10, 15, and 20 ppm of Cd were 
prepared. A Perkins Elmer Optima 4300 DV ICP-OES was then used to determine the 
concentration of the prepared digest. Initial concentration of the particles was then 
calculated using dilution factor and particle size. 
2.3. Gold Nanoparticle Formation 
AuNP of approximately 4 nm were synthesized as described by Duff and 
Baiker134• Initially, 33ml of deionized MilliQ water were combined with 400 111 of 
THPC. In preparation for the next step, 180 ml of MilliQ water are cooled to 7-8°C. 
This chilled water was vigorously stirred and 4 ml of the prepared THPC solution was 
added. Having let the solution stir for 5 min. 6.75ml of 1% chloroauric acid (99.999%) 
was added. The solution was then cooled and stored at 4°C. Size of the gold colloid was 
monitored via UV-Vis absorbance as seen by a shift in peak absorbance as nanoparticle 
size increases. 
2.4. Peptide Synthesis 
Fmoc solid phase peptide synthesis involves the one by one addition of amino 
acids to a polystyrene bead resin. At each stage, an Fmoc protected amino acid is added 
to the growing peptide chain. The protecting group ensures that only one amino acid is 
added at a time. Excess amino acids are then washed away and de-protection of the 
Fmoc group takes place. This general schematic is seen in Figure 22. 
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Figure 22- Fmoc Solid Phase Peptide Synthesis 
Modified from Cojocari 2009 132 
The collagenase degradable sequence XLGPAXC (X representing varytng 
number of glycine spacers) and cathepsin K degradable sequence GGGMGPSGPWGGC 
were synthesized using Fmoc solid phase peptide synthesis. The collagenase sequence 
was chosen as it has been demonstrated to undergo cleavage by collagenase as it mimics 
the collagen repeat sequence -Pro-X-Gly-Pro- (where X can be almost any Amino 
Acid) 135• The cathepsin K sequence chosen was used as it has been demonstrated to be 
an effective sequence for cathepsin K as validated by members of the lab and the 
MALDI-TOF results. 
The collagenase and cathepsin K degradable peptides were synthesized on an 
automated peptide synthesizer (AAPTEC). Upon completion of the synthesis, cleavage 
from the polystyrene resin was done using 95% TFA (tri-fluoracetic acid), 2.5°/o water, 
and 2.5°/o TIPS (triisoproplysilane). The scavenger EDT (ethanedithiol) was then added 
to a final concentration of 2.5% to ensure deprotection of the cysteine protecting group. 
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Following cleavage, the water and acid were removed via rotary evaporation (Buchi 
Rotavapor R-200). The remaining solution was then precipitated in chilled anhydrous 
ethyl ether (Fisher Scientific) and transformed into a pellet via centrifugation (5 min @ 
2000 r.p.m). The pellet was dissolved in chloroform and the process was repeated four 
times to ensure removal of residual cleavage cocktail. The final pellet was left to dry 
overnight, dissolved in water and dialyzed against MilliQ water using a membrane with 
mesh size of 500 Da (8 hr, water changed every 2 hr). The final step was to freeze the 
peptide at -80°C, lyophilize it, and store under argon. 
2.5. MALO/-TOF Analysis of Peptides 
Peptides were analyzed using MALO I-TOF to ensure proper peptide synthesis. 
Solutions of peptides were created at a concentration of 10 f.lM. Solutions were spotted 
onto a Prespotted AnchorChip 96 Set For Proteomics at a volume of 0.5 f.lL 
Measurements were taken on an Autoflex II TOF/TOF. Results were calibrated using the 
peptide standards found on the plate. Approximately 500 shots were taken at a laser 
power of 22% in the range of 500-2000 Da. 
2.6. Probe Asssembly 
The protease-activated QD probes designed have three functional elements: QD, a 
peptide linker, and AuNPs. In addition, both the QD and AuNP surface must be further 
protected by the addition ofPEG. The process of assembling the probe is outlined below. 
45 
2.1.1. Peptide Linker Addition 
The first stage in probe assembly is the addition of peptide linkers the QD surface. 
In the case of the optimization studies the collagenase degradable peptide linkers 136•137 
XLGPAXC (X representing varying number of glycine spacers) were used. Later work 
involving multiplexed probe also used the cathepsin K sensitive GGGMGPSGPWGGC 
sequence. Free carboxylic acids on the PAA polymer coating were activated to produce 
ester leaving groups with the use of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) and sulfo-N-hydroxysuccinimide (sulfo-NHS) via the reaction scheme seen in 
Figure 23. Before addition of the peptide linker, 2-mercaptoethanol was used to 
deactivate excess EDC and prevent peptide linker polymerization. Peptide linkers were 
then added at the desired molar ratios and the conjugation was allowed to proceed 
overnight at room temperature. The resulting reaction mixture was dialyzed against a 
10000 molecular weight cut off cellulose ester membrane to remove excess reagents and 
unreacted peptide. The particles were further purified and concentrated using a 50 kDa 
cutoff centrifugal filter (Amicon). 
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Figure 23 - General Reaction Mechanism for EDC/ Sulfo-NHS mediated Amide Bond Formation 
From http://www. piercenet.com/media/Sulfo-NHS _Reaction_ Figu re03.gif 
2.1.1. AuNP Addition 
The next stage in probe assembly was the addition of AuNP. These were allowed 
to bind to the thiol groups on the cysteine residue near the C-terminus of the designed 
peptide linkers. AuNP was added at the desired molar ratio and allowed to react 
overnight. Any excess AuNP were then removed by centrifugation via a 50 kDa cutoff 
centrifugal filter (Amicon). 
2.1.1. Protection of QD and AuNP Surface with PEG 
In order to increase stability and avoid issues such as nonspecific protein 
adsorption, both the QD surface and AuNP required the addition of PEG. PEG-amine 
(PEG-NH2, 1000 Da) was added to the QD P AA surface using the carbodiimide chemistry 
described earlier at a molar ratio of 500: 1 PEG:QD and allowed to react overnight. 
Excess EDC and PEG-NH2 were removed by dialysis against MilliQ water using a 
membrane with mesh size of 10 KDa (8 hr, water changed every 2 hr). The AuNP 
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surface was then functionalized with PEG-thiol (PEG-SH, 1000 Da). This was added 
at a molar ratio of 100: 1 PEG-SH:AuNP and reacted to the AuNP surface via the thiol 
group on the end of the PEG chain. Following PEG-SH addition, the QD probe mixture 
was vortexed and allowed to react overnight in the fridge at 4°C. The resulting probes 
were then again dialyzed and stored under argon. 
2.7. Probe Optimization Study 
Having established the technique for probe synthesis, optimization of probe 
characteristics was undertaken. The ideal probe for assaying protease activity will have 
the greatest sensitivity to protease activity. This is evidenced through the rate of 
fluorescence recovery exhibited and the overall ratio of fluorescence increase. To 
optimize these characteristics, two key variables were investigated: the number of AuNP 
per QD and the peptide linker length. The molar ratio of AuNP:QD was varied at four 
levels: 5:1, 10:1, 15:1, and 20:1. This was undertaken by varying the molar ratio of 
peptide linkers to QD as described in the probe design above. The length of the peptide 
linker was varied at three levels consisting of 0, 2 and 4 glycine spacers on each side of 
the protease-sensitive site. As amino acids have an average length of approximately 0.38 
nm, this coincides to increasing the peptide linker length by 0, 1.52, and 3.04 nm, 
respectively. 
The first step in characterizing the 12 probe formulations was to determine the 
level of fluorescence quenching in relation to an unquenched QD. For each group, the 
fluorescence of 1 ml of 20 nM probe solution was measured using a fluorometer 
(Fluorolog). Three fluorescent measurements of each group were taken using a 425 .±.JO 
nm excitation fllter and 590 .±....5 emission fllter. These were compared to the fluorescence 
of a control group subjected to the same reaction conditions as the probes, but without 
the addition of AuNP. 
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To determine the level of fluorescence recovery, a second experiment was 
undertaken. For each ofthe 12 groups, 0.5 ml of40 nM probe solution was added to 0.5 
ml containing 0.1 F ALGPA units of collagenase from Clostridium histolyticum (Sigma) 
with a specific activity of0.5 units/mg. An FALGPA unit is defined by the manufacturer 
as the amount of enzyme required to hydrolyze 1.0 Jlm offurylacryloyl-LGPA per min at 
pH 7.5 and 25 °C in the presence of calcium ions. Fluorescence readings were taken of 
the solution in 1 ml disposable plastic cuvettes using a fluorometer (Fluorolog) at 5 min 
intervals for the first hour. The QD probes, having a peak excitation of 592 nm, were 
excited using a 425 ± 10 nm excitation filter and emissions were collected using a 590 ± 
5 nm emission filter. 
2.7. Multiplexing Study 
In order to demonstrate the ability of the probes to be used in multiplexed 
applications, cathepsin K and collagenase activity were simultaneously monitored in 
solution. In addition to the collagenase sensitive probes (emission at 592 nm, degradable 
peptide: GGGGLGPAGGGGC, AuNP:QD ratio of 10:1) used earlier, a new batch of 
cathepsin K sensitive probes (emission at 541 nm, degradable peptide: 
GGGMGPSGPWGGC, AuNP:QD ratio of 10:1) was synthesized as previously 
described. 
In the first experiment, 0.5 ml containing 5 pmol of both collagenase and 
cathepsin K sensitive probes was incubated with 0.5 ml of an enzyme solution containing 
either collagenase (0.1 FALGPA units), cathepsin K (0.005 units), or both. A cathepsin 
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K unit is defined by the manufacturer as the amount of enzyme required to hydrolyze 
1.0 ~ of Phe-Arg per min at pH 7.5 and 25 °C. The solution was excited using a 425 ± 
10 nm filter and readings of collagenase probe fluorescence (590 ± 5 nm emission filter) 
and cathepsin K probe fluorescence (540 ± 10 nm filter) were taken with a fluorometer 
every 5 min for 1 hr. 
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Chapter 3: Results 
3.1. QD Characterization 
3.1.1. TEM Images- Size 
The first parameter that needed to be characterized for QD was their size. This 
was accomplished using TEM imaging. Figure 24 shows such sample images after 
shelling, after PAA-OA water solubilization, and after AuNP addition. It can be seen that 
the QD go from about 7-8nm diameter after shelling to about 30 nm after water 
solubilization. 
Figure 24 - TEM images at various stages - TEM images of the probes after a) ZnS Shelling, b) water 
solubilization, and c) addition of AuNP. TEM images were taken at 60000x. 
3.1.2. ICP/OES- Concentration 
Determining the concentration of QD was the next step and is crucial to ensure 
repeatability of future studies. After digestion of 100 J.!L, ICP measurements were taken 
to get concentrations of Cd in ppm. From this value we can calculate our original stock 
concentration and then using the following equations and approximations we can get the 
particle concentration. 
Length of CdSe Bond= 0 .36nm 
# of Units in Diameter = D 10.36 
# if Cds . S h 4n(units) 2 o e zn p ere = 3 
Weight of Cd per mol of QD = 114 * # of CdSe 
Mol of Stock Sol.=PPM(mg/L)I(Weight Cd/mol QD) 
3.1.3. UV-VIS- Absorbance Spectra 
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Finally, absorbance measurements were taken after core synthesis, shelling, and 
water solubilization. Both peak absorbance and full width at half maximum were 
calculated. Figure 25 shows three sample spectra. The top spectrum is that of just CdSe 
cores. The second spectrum is after 3 Zn/S shells have been added. It can be noted that 
shelling causes a shift in peak absorption. Finally, the third spectrum is for P AA-OA 
water solubilized QD. Again there is a shift in peak absorbance although this shift is a 
small one. 
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Figure 25 -Absorbance Spectra of CdSe , CdSeZnS, and P AA-OA coated QD 
3.2. MALO/-TOF ANAL YS/5 
The successful synthesis of all peptides synthesized was undertaken usmg 
MALDI-TOF analysis. This ensured that the synthesis was completed successfully and 
that no amino acids were left out during synthesis. As well, a study was carried out in 
which spectra of the peptide before and after incubation with protease were taken. This 
was done to ensure that linkers were in fact being cleaved. Figure 22 shows a 
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representative result for GGLGPAGGC before and after cleavage. Of note is the fact 
that we see a disappearance in the main peak of the peptide at around 960 Da indicating 
cleavage is taking place. 
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Figure 26 - MALDI-TOF of Peptide Before and After Digestion 
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3.3. Validation of Probe Functionality 
To ensure that probe assembly was successful, a simple study was run in which a 
batch of probes was incubated with 0.2 mg/ml of collagenase. The emission spectra of 
the probes before and after incubation as well as a control were taken. In Figure 27, we 
see the difference between the control (solid line) and probe (dashed). After 1 hr of 
incubation with collagenase we see a restoration of the emission (dotted line) 
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Figure 27- Validation of Successful Probe -Fluorescence intensity of control (no AuNP, solid line) and 
quenched QD probes (dashed line), and recovered fluorescence of activated QD probes following incubation 
with collagenase (dotted line). 
3.4. Determination of Probe Quenching 
In order to compare the level of quenching produced by the varying linker lengths 
and AuNP:QD ratios, each group was measured with respect to a control with no AuNP. 
The results of these fluorescence measurements can be seen in Figure 28. 
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Figure 28- Degree of Quenching vs. Control - The level of quenching of each of the 12 groups is 
measured with respect to a control using a fluorometer to determine the level of quenching. 
As seen in Figure 28, the magnitude of QD quenching is increased by both 
decreasing the glycine spacer length and increasing the number of AuNP attached to the 
probes. These changes were statistically significant for all the levels evaluated (ANOVA, 
with Tukey's post hoc, p<O.Ol). Based on these results and analysis of the Forster 
formalism, probes containing spacers of greater than 4 glycines were not investigated as 
they would likely result in a dramatic decrease in the level of quenching and thus 
decrease probe performance. 
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3.5. Optimization of Fluorescence Recovery of Probes 
Having determined the varying levels of probe quenching, the next step was to 
compare the fluorescence recovery of the various probes in the presence of protease. All 
12 groups were exposed to a 0.2 mg/ml solution of collagenase and the fluorescence was 
monitored over the first hour. The results ofthis study can be seen in Figure 29. Of note 
is the absence of the probes with 0 length spacers. Probes with 0 glycine spacers had 
minimal fluorescent recovery, likely due to impaired protease access to the degradation 
site at such short linker lengths. 
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The probe formulation demonstrating the most desirable response in the 
presence of enzyme uses degradable peptide linkers with 4 glycine spacers to join AuNP 
to QD at a ratio of 10:1 (Figure 3b, filled circles dashed line). These particles have good 
initial quenching and high overall fluorescence recovery, and also exhibit a fast and linear 
response in the initial 15 min of activation providing sensitivity as well as ease of 
quantification. 
3.6. Multiplexing Probes Sensitive to Collagenase and Cathepsin K 
In order to demonstrate the ability to multiplex probes, a solution containing both 
collagenase and cathepsin K probes was incubated with either or both of the proteases. 
As demonstrated in Figure 30, the addition of a single enzyme results in activation of a 
single QD probe (panels a and b) with only low levels of cross-activation of the non-
specific QD. The specific activation of two QD probes at similar levels of intensity was 
accomplished upon exposure to the dual enzyme solution (Figure 30, c). The ability of 
QD to specifically recognize individual proteases with good signal to noise means that 
using this technology in multiplexed applications is quite feasible. 
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59 
Chapter 4: Discussion 
This work has demonstrated the ability to produce protease-activated quantum dot 
probes. Initially, a proof of concept study was carried out which validated the probe 
assembly technique. It was found that it is important to first attach the linkers, then the 
AuNP, and finally to backfill with PEG. If the QD surface is first protected with PEG, 
attachment of the linker and AuNP become much more difficult. 
Having validated general functionality, a study was designed to optimize probe 
functionality. In order to better analyze the levels of quenching of the 12 groups and gain 
insight into probe conformation, the data was fit to the Forster formalism: 
In this equation, E represents the FRET or shielding efficiency (% of fluorescence 
shielded), n is the number of AuNP quenchers per QD, r is the separation of the QD and 
AuNP, and R0 is the Forster radius. Previous work by Gueroui et a/. 138 has shown the Ro 
for AuNP/QD quenching to be 7.5 nm. Solving for r at the 0, 2 and 4 spacer linker 
lengths yields separations of 2.97, 2.48, and 1.63 nm. As linker length is increased, the 
ratio of spacing/linker length decreases, indicating the AuNP are bending more towards 
the QD. 
The study carried out to optimize probe functionality showed that probes with 4 
spacers and AuNP:QD ratio of 10:1 produced the best results. This validated the theory 
that there is a distinct interplay between the effects of steric hindrance/ cleavage site 
accessibility and overall probe quenching. Further, when examining the recovery in 
60 
fluorescence of the probes, it is seen that this recovery can be modeled as a logistic 
function. As the enzymes cleave AuNP from the QD, steric hindrance is reduced and 
fluorescence recovery accelerates before reaching steady state and leveling off. This 
effect is more evident in the groups with higher molar ratios of AuNP:QD. This again 
highlights the complex interactions and competing factors that are involved in this probe 
design. 
Finally, a study was undertaken to demonstrate the multiplexing ability of these 
protease-activated QD probes. The ease of designing peptide linkers specific to any 
protease of choice was demonstrated. By scanning literature and/or using tools such as 
the MEROPS peptidase database, one could easily select several key sequences 
pertaining to the proteases one wishes to study. Each of a series of batches of QD of 
various sizes (and thus with orthogonal emission spectra) could then be used to assemble 
probes with a protease target of choice. A cocktail of these would be able to monitor 
several proteases concurrently in addition to enabling quantification of the data. 
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Chapter 4: Conclusions 
Protease-Activated quantum dot probes have been synthesized and it has been 
shown that their fluorescence change correlates with protease activity. Having validated 
general synthesis strategy, a study was carried out which allowed probe configuration to 
be optimized. 
The effect of linker length and AuNP:QD ratio on fluorescence recovery were 
explored and it was shown that probes with 4 spacers and 10: 1 AuNP:QD ratio produced 
optimal results. This was the configuration at which the steric hindrance caused by 
shorter linkers and more AuNP balanced with the gain in potential fluorescent recovery. 
To further demonstrate the potential applications of these probes, it was shown that 
multiple probes each sensitive to a specific protease can simultaneously be used to 
monitor protease activity. 
This work has laid the foundation for protease-activated quantum dot probes. 
Further work needs to be carried out to demonstrate the functionality of the probes in a 
complex biological environment. This work can be carried out using cell lines such as 
NIH-3T3, HT1080, and MCF-7 with varying degrees of metastatic potential. Upon 
demonstration of functionality in vitro, an in vivo model using immuno-compromised 
Balb/c nude mice model should be used to validate the probes ability to quantify protease 
expression in various tumor types. 
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